Soleno Announces Jennifer Fulk as CFO; Mackaness to Retire by End of Q1
Soleno Therapeutics will replace CFO James Mackaness, who will retire by end of Q1 and continue as consultant through 2026, with Jennifer Fulk, a 20-year public-company finance veteran with 15 years at Eli Lilly. Fulk will guide financial strategy during the U.S. rollout of VYKAT XR and upcoming EU approvals.
1. CFO Appointment
Soleno Therapeutics has named Jennifer Fulk as its new Chief Financial Officer, succeeding James Mackaness. Fulk brings over two decades of public company finance leadership, including 15 years at Eli Lilly and recent CFO roles at Talkspace and 120Water, where she led financial reporting, investor relations and operational efficiency.
2. Transition Plan
James Mackaness will retire by the end of the first quarter but remain as a consultant through year-end to ensure a smooth handover. The company will rely on Fulk’s expertise to maintain financial discipline and support the ongoing U.S. rollout of VYKAT XR, as well as pursue regulatory approvals in the EU and other territories.